Annual Information Update
April 1, 2010 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announces its Annual Information Update in accordance with the requirements of Prospectus Rule 5.2. This is in relation to information that has been published or made available to the public between April 1, 2009 and March 31, 2010.
The information referred to in this Annual Information Update was correct at the time the information was published, but some information may now be out of date. The information appears by way of record and the Company is under no obligation to update it.
| 1. | Announcements made via a RIS |
The documents listed below were published via a Regulatory Information Service on or around the dates indicated.
| 25-Mar-10 | Shire Presents Positive Data for Patients with Type 1 Gaucher Disease who Switched to VPRIV™ |
| 25-Mar-10 | Publication of Shire plc’s Annual Report 2009 |
| 18-Mar-10 | Director/PDMR Shareholding |
| 16-Mar-10 | Shire Receives INTUNIV Paragraph IV Notice Letter from Teva Pharmaceuticals |
| 15-Mar-10 | New Board Director Appointed |
| 11-Mar-10 | Director/PDMR Shareholding |
| 09-Mar-10 | Director/PDMR Shareholding |
| 05-Mar-10 | Director/PDMR Shareholding |
| 04-Mar-10 | District Court Upholds FDA’s Grant of 5-Year Market Exclusivity to VYVANSE® |
| 03-Mar-10 | Director/PDMR Shareholding |
| 03-Mar-10 | Director/PDMR Shareholding |
| 02-Mar-10 | Supplementary Reporting Announcement |
| 01-Mar-10 | Elections for Interim Dividend in Respect of the Six Months to December 31, 2009 |
| 01-Mar-10 | Total Voting Rights |
| 01-Mar-10 | Shire Announces FDA Approval of VPRIV™ (velaglucerase alfa for injection) for the Treatment of Type 1 Gaucher Disease |
| 24-Feb-10 | Shire Provides Update on Biologics License Application (BLA) Filing for REPLAGAL® (agalsidase alfa) with the U.S. Food and Drug Administration (FDA) |
| 19-Feb-10 | Excellent results in a transformational year for Shire; core product sales up 25% |
| 11-Feb-10 | Shire Presents Positive Efficacy and Safety Data for velaglucerase alfa in Treatment of Naïve Patients with Type 1 Gaucher Disease |
| 04-Feb-10 | Full Year 2009 results date notification – 19 February 2010 |
| 01-Feb-10 | Total Voting Rights |
| 26-Jan-10 | Holding(s) in Company |
| 18-Jan-10 | Directorate Change |
| 04-Jan-10 | Total Voting Rights |
| 29-Dec-09 | Director/PDMR Shareholding |
| 23-Dec-09 | Dr Michael Rosenblatt to step down as non-executive director |
| 22-Dec-09 | Shire Submits Biologics License Application (BLA) for REPLAGAL® with the U.S. Food and Drug Administration (FDA) |
| 16-Dec-09 | Membership of Board Committees |
| 16-Dec-09 | Director/PDMR Shareholding |
| 14-Dec-09 | Director/PDMR Shareholding |
| 11-Dec-09 | Director/PDMR Shareholding |
| 07-Dec-09 | Holding(s) in Company |
| 02-Dec-09 | Shire and Teva Settle Litigation Concerning Supply of ADDERALL XR Authorized Generic |
| 01-Dec-09 | Total Voting Rights |
| 24-Nov-09 | Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease |
| 23-Nov-09 | Block listing six monthly return |
| 12-Nov-09 | PDMR Shareholding |
| 04-Nov-09 | FDA Grants Priority Review for Shire’s velaglucerase alfa for Type 1 Gaucher Disease |
| 03-Nov-09 | Directors/PDMR Shareholding |
| 02-Nov-09 | Total Voting Rights |
| 02-Nov-09 | New Shire Board member |
| 30-Oct-09 | 3rd Quarter Results - Shire continues to deliver excellent growth from core products |
| 26-Oct-09 | FDA Determines VYVANSE® was Properly Granted Five-Year Market Exclusivity |
| 22-Oct-09 | Third quarter 2009 results date notification – October 30, 2009 |
| 21-Oct-09 | Shire Targets Fourth Quarter Filing of BLA for REPLAGAL® for Fabry Disease with U.S. FDA |
| 15-Oct-09 | Holding(s) in Company |
| 01-Oct-09 | Total Voting Rights |
| 25-Sep-09 | Director/PDMR Shareholding |
| 22-Sep-09 | Director/PDMR Shareholding |
| 18-Sep-09 | Director/PDMR Shareholding |
| 08-Sep-09 | Update on velaglucerase alfa |
| 04-Sep-09 | Director/PDMR Shareholding |
| 03-Sep-09 | Director/PDMR Shareholding |
| 03-Sep-09 | Shire Announces FDA Approval of Once-Daily INTUNIV™ (guanfacine) Extended Release Tablets for the Treatment of ADHD in Children and Adolescents Aged 6 to 17 |
| 01-Sep-09 | Total Voting Rights |
| 01-Sep-09 | Elections for interim dividend in respect of the six months to June 30, 2009 |
| 01-Sep-09 | Shire Completes Submission of NDA for velaglucerase alfa for Type 1 Gaucher disease and Reports Positive Results for Remaining Two Phase III Trials |
| 21-Aug-09 | Half Yearly Report |
| 19-Aug-09 | Director/PDMR Shareholding |
| 07-Aug-09 | Membership of Board Committees |
| 05-Aug-09 | Q2 results - Core portfolio of products delivers 20% sales growth |
| 03-Aug-09 | Total Voting Rights |
| 03-Aug-09 | Shire Reports Positive Results from First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions with FDA |
| 28-Jul-09 | FDA Issues Complete Response Letter for INTUNIV™ (guanfacine) Extended Release for the Treatment of ADHD in Children and Adolescents |
| 21-Jul-09 | Second quarter 2009 results date notification – August 5, 2009 |
| 16-Jul-09 | Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease |
| 09-Jul-09 | Dr Jeffrey Leiden appointed to Vertex Board. |
| 07-Jul-09 | Shire has filed a treatment protocol for velaglucerase alfa for Gaucher Disease |
| 01-Jul-09 | Total Voting Rights |
| 01-Jun-09 | Total Voting Rights |
| 26-May-09 | Block Listing Six Monthly Return |
| 22-May-09 | Director/PDMR Shareholding |
| 12-May-09 | Director/PDMR Shareholding |
| 01-May-09 | Total Voting Rights |
| 30-Apr-09 | Shire begins the year with a strong performance |
| 28-Apr-09 | Results of the Annual General Meeting held on April 28, 2009 |
| 20-Apr-09 | First quarter 2009 results date notification – April 30, 2009 |
| 02-Apr-09 | Shire files lawsuit against Natco Pharma for infringement of FOSRENOL® (lanthanum carbonate) patents |
| 01-Apr-09 | Director/PDMR Shareholding |
| 01-Apr-09 | Holding(s) in Company |
| 01-Apr-09 | Total Voting Rights |
| 01-Apr-09 | Annual Information Update |
| 2. | Documents filed with the Securities and Exchange Commission (“SEC”) |
The Company submitted filings to the SEC in compliance with its obligations under national laws and rules dealing with the regulation of securities, issuers of securities and securities markets by virtue of having American Depository shares admitted to trading on the NASDAQ. Full details of these filings can be found on the SEC’s website at www.sec.gov.
| 3. | Documents filed with Companies Registry, Jersey |
| Date of Delivery | Document |
| 24-Feb-10 | Annual Return |
01-May-09 | Special Resolution passed on April 28, 2009 |
| 22-Apr-09 | Annual Report and Accounts for the year ended December 31, 2008 |
| 4. | Documents sent to Shareholders |
The following documents were published and sent to shareholders, and are available on the Company’s website.
| Date of Delivery | Document |
| 25-Mar-10 | Annual Report and Accounts for the year ended December 31, 2009 |
| 25-Mar-10 | Notice of 2010 Annual General Meeting |
A copy of this Annual Information Update and copies of the documents referred to in it can be obtained from the Deputy Company Secretary at the Company’s registered office.
For further information please contact:
| Investor Relations | Cléa Rosenfeld (Rest of the World) | +44 1256 894 160 |
| | Eric Rojas (North America) | +1 781 482 0999 |
Notes to editors
SHIRE PLC
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company’s website: www.shire.com.
